Teva Pharmaceutical Industries Ltd (TEVA) stock saw a decline, ending the day at $20.44 which represents a decrease of $-0.50 or -2.39% from the prior close of $20.94. The stock opened at $20.95 and ...

The following is a summary of “Industry Payments and Branded Glatiramer Acetate Prescribing in the US Medicare Program,” ...

Gather's co-owner talks about his early inspiration in a Jewish environmental program and how he’s kept the restaurant ...

The authors write "The Food, Drug and Cosmetic Law Section of the New York State Bar Association is delving into the changing ...

Teva Pharmaceutical Industries Limited ( NYSE: TEVA) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2025 11:15 AM ET Richard Francis - President and CEO Eric Hughes - Head of R&D and Chief ...

Teva Pharmaceuticals CEO Richard Francis reflects on company performance in 2024, drug pricing, getting more drugs to market ...

Teva was established as the European commercialisation partner of FYB201, Formycon's biosimilar to ranibizumab (Lucentis).

Analyst Jason Gerberry from Bank of America Securities reiterated a Buy rating on Teva Pharmaceutical (TEVA – Research Report) and increased ...

Klinge Biopharma GmbH (Klinge) holds the exclusive global commercialization rights for FYB203, Formycon's biosimilar candidate to ...

Timing Trades in Teva Pharmaceutical Industries Limited American Depositary Shares TEVA can be Risky if you Don't Have ...

Teva Pharmaceutical collaborates with Klinge Biopharma and Formycon AG to commercialize Formycon's biosimilar candidate to ...

The Federal Circuit's recent ruling that patents listed in the FDA's Orange Book must cover the active ingredient of a drug has sparked significant debate in the pharmaceutical industry. The court's ...